{"entity":{"id":"chris-hillis","kind":"person","name":"Chris Hillis","aka":[],"tldr":"Blood cancer specialist who leads the Juravinski Cancer Centre, one of Ontario's largest integrated cancer programmes, as Vice President of Oncology.","summary":"Chris Hillis is Vice President, Oncology and Site Executive for the Juravinski Hospital and Cancer Centre at Hamilton Health Sciences, leading one of Ontario's largest integrated cancer programmes, and serves as Regional Vice President for the Hamilton Niagara Haldimand Brant Regional Cancer Program with Ontario Health. He is a malignant haematologist focused on chronic lymphocytic leukaemia and myeloproliferative neoplasms and an Associate Professor at McMaster University. He previously served as Chief of Oncology and Associate Chief Medical Information Officer, holds an MSc in quality improvement and patient safety, and leads a CIHR-funded research programme on making clinical trial outcomes more meaningful to patients with haematological malignancies.","asOf":"2026-09-10","links":[{"label":"Source: Hamilton Health Sciences senior leadership team","url":"https://www.hamiltonhealthsciences.ca/about-us/our-organization/senior-leadership-team/"}],"tags":["leadership","clinician-scientist","haematology"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["juravinski"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["leukemia-and-lymphoma"],"dependsOn":[],"notes":[],"role":"Vice President, Oncology and Site Executive, Juravinski Hospital and Cancer Centre, Hamilton Health Sciences","institutionId":"juravinski","specialisms":["Malignant haematology","Chronic lymphocytic leukaemia","Myeloproliferative neoplasms","Quality improvement"],"profiles":[{"label":"Institution senior leadership page","url":"https://www.hamiltonhealthsciences.ca/about-us/our-organization/senior-leadership-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hillis+C%5BAuthor%5D+AND+hematology"}],"papers":[{"title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","journal":"Leukemia & Lymphoma","year":2015,"doi":"10.3109/10428194.2015.1091929"},{"title":"A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre","journal":"Gynecologic Oncology","year":2021,"doi":"10.1016/j.ygyno.2021.01.014"},{"title":"Gender and BCR‐ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia","journal":"European Journal of Haematology","year":2015,"doi":"10.1111/ejh.12597"}]},"route":"/people/chris-hillis/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"institution":[{"id":"juravinski","kind":"institution","name":"Juravinski Cancer Centre / Escarpment Cancer Research Institute","route":"/institutions/juravinski/"}],"journal":[{"id":"leukemia-and-lymphoma","kind":"journal","name":"Leukemia & lymphoma","route":"/journals/leukemia-and-lymphoma/"}]}}